On August 31, 2023, Precision BioSciences, Inc. announced resignation of Shane Barton as the Company?s Corporate Controller, effective September 15, 2023, at which time he will cease serving as the principal accounting officer. On September 6, 2023, the Company?s Board of Directors designated Alex Kelly, the Company?s Chief Financial Officer and principal financial officer, to also serve as the Company?s principal accounting officer effective upon Mr. Barton?s departure. Mei Burris, the Company?s Senior Director of Finance and Corporate Controller, will assume responsibilities previously performed by Mr. Barton following his departure.

Ms. Burris has held roles of increasing responsibility at the Company since February 2019, including most recently Director of Investor Relations and Finance. Prior to this, from August 2017 to February 2019, Ms. Burris served as Assistant Controller of Heat Biologics, Inc. (now Nighthawk Biosciences, Inc.). From April 2014 to August 2017, Ms. Burris was with Cempra Pharmaceuticals, Inc. prior to its merger with Melinta Therapeutics, Inc, where Ms. Burris served as Senior Accountant.

Ms. Burris is a certified public accountant and earned her Bachelor of Science in Business Administration from West Virginia University.